Get started
Author

Nancy I. Wedel

Observed names: N I Wedel, N Wedel, N. I. Wedel, N. Wedel, NANCY I. WEDEL, NANCY WEDEL, Nancy I Wedel, Nancy Wedel
Institutions: University of Maryland, Baltimore, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, Cornell University, Princess Margaret Cancer Centre, Dana-Farber Cancer Institute, Duke Medical Center, Weill Cornell Medicine
Observed institutions: Boston University, University of Maryland, Baltimore, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, Oregon Health & Science University, University of Pittsburgh, University of California, San Francisco, Washington University in St. Louis, Cornell University, Princess Margaret Cancer Centre, Amsterdam UMC Location University of Amsterdam, Hôpital Charles-Nicolle, Dana-Farber Cancer Institute, Duke Medical Center, UPMC Hillman Cancer Center, Stanford Medicine, XOMA (United States), PDL BioPharma (United States), Weill Cornell Medicine, Saint Louis University, Université de Rouen Normandie, University of Colorado Denver, Stanford University
OpenAlex ID: A5083193141
Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia
2005 · Eric J. Feldman, Joseph Brandwein, et al. · Journal of Clinical Oncology · 249
PDF
Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.
1987 · L E Spitler, M del Rio, et al. · PubMed · 211
Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis
1997 · Brett P Giroir, Peter A Quint, et al. · The Lancet · 176
Inhibition of Endotoxin-Induced Cytokine Release and Neutrophil Activation in Humans by Use of Recombinant Bactericidal/Permeability-Increasing Protein
1995 · M. A. M. von der Mohlen, A. N. Kimmings, et al. · The Journal of Infectious Diseases · 120
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195
2003 · E Feldman, M Kalaycio, et al. · Leukemia · 84
PHASE I TRIAL OF HuM291, A HUMANIZED ANTI-CD3 ANTIBODY, IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM LIVING DONORS1
2000 · Douglas J. Norman, Flavio Vincenti, et al. · Transplantation · 68
Ultrastructural effects of Clostridium difficile toxin B on smooth muscle cells and fibroblasts
1983 · Nancy Wedel, Paul Toselli, et al. · Experimental Cell Research · 53
Phase I/II Study of Murine Monoclonal Antibody-Ricin A Chain (XOMAZYME-Mel) Immunoconjugate plus Cyclosporine A in Patients with Metastatic Melanoma
1993 · K Selvaggi, E A Saria, et al. · Journal of Immunotherapy · 51
Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, Gram-negative sepsis
1992 · RICHARD N. GREENBERG, KATHY M. WILSON, et al. · Critical Care Medicine · 37
A Phase I Safety and Pharmacokinetic Study of a Recombinant Amino Terminal Fragment of Bactericidal/ Permeability-increasing Protein in Healthy Male Volunteers
1996 · Robert J. Bauer, Mark L. White, et al. · Shock · 34
Plasma bactericidal/permeability-increasing protein concentrations in critically ill children with the sepsis syndrome
1995 · HECTOR R. WONG, LESLEY A. DOUGHTY, et al. · The Pediatric Infectious Disease Journal · 22
Recombinant endotoxin-binding protein (rBPI23) attenuates endotoxin-induced circulatory changes in humans.
1995 · R J de Winter, M A von der Möhlen, et al. · PubMed · 22
COAGULOPATHY FOLLOWING MAJOR LIVER RESECTION: THE EFFECT OF rBPI21 AND THE ROLE OF DECREASED SYNTHESIS OF REGULATING PROTEINS BY THE LIVER
2001 · Catharina Meijer, Marinus J. Wiezer, et al. · Shock · 21
Randomized Placebo-controlled Study of E5 Monoclonal Antiendotoxin Antibody
1990 · Kenneth Gorelick, Patrick J. Scannon, et al. · Palgrave Macmillan UK eBooks · 21
Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.
1991 · R Gonzalez, P Salem, et al. · PubMed · 16
Randomized, double-blind phase II study of anti-endotoxin antibody (E5) as adjuvant therapy in humans with serious gram-negative infections.
1991 · R N Greenberg, K M Wilson, et al. · PubMed · 12
916-91 Recombinant Endotoxin-binding Protein (rBPI23) Attenuates Endotoxin-induced Circulatory Changes in Humans
1995 · Robbert J. de Winter, Marijke A.M. von der Mohlen, et al. · Journal of the American College of Cardiology · 11
PDF
Pharmacokinetics and Safety of Antiendotoxin Antibody E5 (e5) in Normal Subjects
1990 · Nancy I. Wedel, Kenneth J. Gorelick, et al. · Critical Care Medicine · 10
Pharmacokinetics of a Recombinant Modified Amino Terminal Fragment of Bactericidal/Permeability‐Increasing Protein (rBPI21) in Healthy Volunteers
1999 · Robert J. Bauer, Nancy Wedel, et al. · The Journal of Clinical Pharmacology · 8
Preservation of ultrastructure of cells cultured on protein—hydroxyethylmethacrylate hydrogels
1983 · Paul Toselli, Barbara Faris, et al. · Journal of Ultrastructure Research · 8
E5 Antiendotoxin Antibody in Gram-negative Sepsis
1990 · Kenneth J. Gorelick, Nancy I. Wedel, et al. · Critical Care Medicine · 6
rBPI2, IN THE PREVENTION OF THE INFLAMMATORY RESPONSE AFTER LIVER RESECTION IN PATIENTS: RESULTS OF THE LOW DOSE PHASE.
1997 · C. Meijer, C. E. Hack, et al. · Shock · 4
PHASE I DOSE ESCALATION TRIAL OF HuM 291, A HUMANIZED ANTI-CD3 ANTIBODY, IN LIVING DONOR KIDNEY RECIPIENTS
1999 · Douglas Norman, Flavio Vincenti, et al. · Transplantation
Endogenous Bactericidal/permeability Increasing Protein Levels in Children With the Sepsis Syndrome
1995 · Hector R. Wong, Joseph Carcillo, et al. · Critical Care Medicine
Preclinical Development of Xomen™-E5
1990 · Ada H. C. Kung, Elizabeth A. Saria, et al. · Palgrave Macmillan UK eBooks
Works count: 26
Citation count: 1,244
H-index: 15
I10-index: 18
Year
Topic
Type